Sign InSign Up

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’ - The Guardian

AI Summary1 min read

TL;DR

Novo Nordisk's next-gen weight-loss drug CagriSema is labeled 'obsolete' after failing to match Eli Lilly's Zepbound in trials, causing a 15% stock drop and erasing Wegovy-era gains.

Tags

Novo Nordiskweight-loss drugEli Lillystock dropclinical trial
  1. Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’  The Guardian
  2. Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial  CNBC
  3. Novo Nordisk slumps further on weight loss drugs in fight with Eli Lilly  Axios
  4. Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out  Reuters
  5. Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price  Fierce Biotech

Visit Website